Who
Thomas Sciascia
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Trevi Therapeutics; SVP Clin Dev & Reg Aff & CMO, Penwest Pharmaceuticals Co.
In numbers
- Trades disclosed
- 48
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $290K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 9 Feb 2006
- Last trade
- 19 Feb 2026
- Last filed
- 20 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Feb 2026filed 20 Feb 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 31 May 2025filed 3 Jun 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 25 Mar 2025filed 26 Mar 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,631 at $0.00 | filing |
| 25 Mar 2025filed 26 Mar 2025 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $3,7622,631 at $1.43 | filing |
| 25 Mar 2025filed 26 Mar 2025 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K2,631 at $6.60 | filing |
| 10 Mar 2025filed 12 Mar 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —116,000 at $0.00 | filing |
| 19 Aug 2024filed 21 Aug 2024 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,496 at $0.00 | filing |
| 19 Aug 2024filed 21 Aug 2024 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $24K16,496 at $1.43 | filing |
| 19 Aug 2024filed 21 Aug 2024 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $49K16,496 at $2.96 | filing |
| 16 Aug 2024filed 16 Aug 2024 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,660 at $0.00 | filing |
| 16 Aug 2024filed 16 Aug 2024 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $27K18,660 at $1.43 | filing |
| 16 Aug 2024filed 16 Aug 2024 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $52K18,660 at $2.76 | filing |
| 15 Aug 2024filed 16 Aug 2024 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,745 at $0.00 | filing |
| 15 Aug 2024filed 16 Aug 2024 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $18K12,745 at $1.43 | filing |
| 15 Aug 2024filed 16 Aug 2024 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $36K12,745 at $2.79 | filing |
| 14 Aug 2024filed 16 Aug 2024 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —100 at $0.00 | filing |
| 14 Aug 2024filed 16 Aug 2024 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $143100 at $1.43 | filing |
| 14 Aug 2024filed 16 Aug 2024 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $275100 at $2.75 | filing |
News
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual MeetingTRVI · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Thomas Sciascia; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.